Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Publisher Correction: Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.

Nature cancer·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

A 10-year-long ongoing complete response to vismodegib as first-line treatment in adult metastatic medulloblastoma.

Acta oncologica (Stockholm, Sweden)·2026
Same author

Clinical validation of a high-performance somatic exome sequencing assay: from target-enrichment strategy to variant calling.

NPJ genomic medicine·2026
Same author

Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors.

Neuro-oncology advances·2026

Related Experiment Video

Updated: Apr 12, 2026

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

13.6K

Multicentric Low-Grade Gliomas.

Vishwajith Sridharan1, Laura M Urbanski2, Wenya Linda Bi3

  • 1Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

World Neurosurgery
|May 26, 2015
PubMed
Summary
This summary is machine-generated.

Multicentric low-grade gliomas, rare brain tumors, can have distinct presentations and prognoses. This case highlights their unique pathogenesis, imaging, and molecular features, impacting clinical management.

Keywords:
AstrocytomaGangliogliomaLow-grade gliomaMulticentric gliomaPlatelet-derived growth factor receptor amplificationTumor progression

More Related Videos

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

3.1K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.5K

Related Experiment Videos

Last Updated: Apr 12, 2026

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

13.6K
Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

3.1K
Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation
09:43

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

8.5K

Area of Science:

  • Neuro-oncology
  • Neuropathology
  • Neuroradiology

Background:

  • Multicentric low-grade gliomas are rare brain tumors occurring in multiple, distinct brain regions.
  • These tumors can exhibit unique pathological and imaging features, often associated with a poorer prognosis.

Observation:

  • A 49-year-old man presented with headaches and was found to have concurrent non-enhancing lesions in the temporal lobe and cerebellum.
  • The temporal lesion progressed to contrast enhancement and was diagnosed as a grade II ganglioglioma.
  • The cerebellar lesion later enhanced and was identified as a grade II astrocytoma.

Findings:

  • Tumor growth rate, pathology, imaging, and molecular profiles significantly influence the clinical course of multicentric low-grade gliomas.
  • PDGFRA amplifications and IDH1 wild-type status may correlate with accelerated tumor progression and recurrence.

Implications:

  • Understanding the molecular signatures and imaging characteristics is crucial for managing multicentric low-grade gliomas.
  • Further research is needed to stratify risk and guide treatment strategies for these rare tumors.